【摘要】 目的探讨肺曲霉病急性期患者甘露聚糖结合凝集素(MBL)及T细胞亚群的变化。方法收集2013年5月~2015年5月就诊于山东省胸科医院呼吸科的肺曲霉病患者51例,同时选52例健康查体者作为对照组,采用Elisa方法检测血清MBL和半乳甘露聚糖(GM)的水平。同时分离外周血单个核细胞,通过流式细胞仪检测测定CD3~+CD4~+T淋巴细胞百分比、CD3~+CD8~+T淋巴细胞百分比及CD3~+CD4~+/CD3~+CD8~+T淋巴细胞比值。结果肺曲霉病组、健康对照组血清MBL水平为197.96±148.16和120.25±98.65μg/mL,P<0.05,差异有统计学意义;血清GM水平分别为0.94±0.77μg/L和0.32±0.16μg/L,P<0.05,差异有统计学意义。肺曲霉病组、健康对照组CD3~+CD4~+T淋巴细胞百分比分别为33.07±7.97、40.32±7.30(P<0.05),CD3~+CD8~+淋巴细胞百分比为33.00±8.29、25.98±6.65(P<0.05),CD3~+CD4~+/CD3~+CD8~+T淋巴细胞比值为1.08±0.47、1.68±0.65(P<0.05)。结论肺曲霉病组患者的MBL及CD3~+CD4~+T淋巴细胞、CD3~+CD8~+T淋巴细胞、CD3~+CD4~+/CD3~+CD8~+T淋巴细胞比值会出现显著的变化,可以初步评估患者机体免疫状态,也为肺曲霉病的免疫增强治疗提供了理论依据。更多还原

【Abstract】 Objective To investigate the role of mannan-binding lectin(MBL)level and changes of T-lymphocyte subsets on the patients with pulmonary aspergillosis.Methods From May 2013 to May 2015,51 patients were enrolled into disease group,52 healthy adults were enrolled into normalcontrol group.The levels of MBL and Galactomannanwere detected by Enzyme-linked Immunosorbent Assay(ELISA).The percentages of CD3~+CD4~+T cells,CD3~+CD8~+T cells,and the ratio of CD3~+CD4~+/CD3~+CD8~+T cells were determined by flow cytometer.Results The express of MBL in disease group(197.96±148.16μg/ml)was significantly higher than that of normal group(120.25±98.65)(P<0.05).The serum galactomannan(GM)level of disease group(0.94±0.77μg/L)was significantly higher than that of normal group(0.32±0.16μg/L).The percentages of CD3~+CD4~+T cells and CD3~+CD8~+T cells were(33.07±7.9)%,(40.32±7.30)%(P<0.05),(33.00±8.29)%,(25.98±6.65)%(P<0.05)in disease group and normal group,respectively.The ratios of CD3~+CD4~+/CD3~+CD8~+T cells in disease group and normal group were 1.09±0.47,1.68±0.65(P<0.05),respectively.Conclusion There was significant change of MBL level and the percentages of T-lymphocyte subset in patients with pulmonary aspergillosis compared with control group.Immunotherapy may improve the efficacy of pulmonary aspergillosis.Through the change of T-lymphocyte subset can preliminary assessment the body’s immune status in patients,at the same time,providing a theoretical basis for immune enhancement therapy in pulmonary aspergillosis.更多还原